Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBITDA (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed EBITDA for 14 consecutive years, with -$11.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 52.2% year-over-year to -$11.3 million, compared with a TTM value of -$73.1 million through Dec 2025, up 33.79%, and an annual FY2025 reading of -$85.3 million, up 29.86% over the prior year.
  • EBITDA was -$11.3 million for Q4 2025 at Enanta Pharmaceuticals, up from -$18.4 million in the prior quarter.
  • Across five years, EBITDA topped out at -$11.3 million in Q4 2025 and bottomed at -$39.5 million in Q1 2023.
  • Average EBITDA over 5 years is -$28.8 million, with a median of -$30.2 million recorded in 2021.
  • The sharpest move saw EBITDA tumbled 150.11% in 2021, then soared 52.2% in 2025.
  • Year by year, EBITDA stood at -$30.4 million in 2021, then rose by 1.3% to -$30.0 million in 2022, then fell by 16.24% to -$34.9 million in 2023, then surged by 32.51% to -$23.5 million in 2024, then skyrocketed by 52.2% to -$11.3 million in 2025.
  • Business Quant data shows EBITDA for ENTA at -$11.3 million in Q4 2025, -$18.4 million in Q3 2025, and -$18.9 million in Q2 2025.